PATIENT PREFERENCE-BASED UTILITY WEIGHTS FROM THE FUNCTIONAL ASSESSMENT OF CANCER THERAPY-GENERAL (FACT-G) IN WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER RECEIVING LETROZOLE PLUS LAPATINIB OR LETROZOLE ALONE

被引：5
|
作者：
Delea, T. E. [1 ]
Sofrygin, O. [1 ]
Amonkar, M. [2 ]
机构：
[1] PAI, Brookline, MA USA
[2] GlaxoSmithKline Inc, Philadelphia, PA USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72194-X
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A43 / A44
页数：2
相关论文
共 50 条
  • [41] Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy
    Paul, D.
    Vukelja, S. J.
    Holmes, F. A.
    Blum, J.
    McIntyre, K. J.
    Kumar, A. R.
    Lindquist, D. L.
    Osborne, C. R.
    Sanchez, I. J.
    Goldschmidt, J. H.
    Wang, Y.
    Asmar, L.
    Lee, M. E.
    Wu, N.
    Logie, K.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2013, 73
  • [42] Patient-reported outcomes in systemic AL amyloidosis with functional assessment of cancer therapy-general (FACT-G) and patient-reported outcomes measurement information system-global health (PROMIS-GH) in a real-world population
    Chakraborty, Rajshekhar
    Rybicki, Lisa
    Tomer, Jacqulyn
    Samaras, Christy J.
    Faiman, Beth M.
    Valent, Jason
    Majhail, Navneet S.
    LEUKEMIA & LYMPHOMA, 2019, 60 (14) : 3544 - 3551
  • [43] Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up
    Regan, Meredith M.
    Neven, Patrick
    Giobbie-Hurder, Anita
    Goldhirsch, Aron
    Ejlertsen, Bent
    Mauriac, Louis
    Forbes, John F.
    Smith, Ian
    Lang, Istvan
    Wardley, Andrew
    Rabaglio, Manuela
    Price, Karen N.
    Gelber, Richard D.
    Coates, Alan S.
    Thuerlimann, Beat
    LANCET ONCOLOGY, 2011, 12 (12): : 1101 - 1108
  • [44] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
    Moller, A. H.
    Oddershede, L.
    VALUE IN HEALTH, 2019, 22 : S483 - S483
  • [45] Health-related quality of life of postmenopausal women with hormone receptor-positive, HER2-advanced breast cancer treated with ribociclib plus letrozole: Results from MONALEESA-2.
    Verma, Sunil
    O'Shaughnessy, Joyce
    Burris, Howard A.
    Campone, Mario
    Alba, Emilio
    Chandiwana, David
    Manson, Stephanie
    Sutradhar, Santosh C.
    Monaco, Mauricio
    Janni, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31)
  • [46] COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Buehler, A.
    Kim, H. S. J.
    Fahham, L.
    Dionne, P. A.
    Castilho, G.
    VALUE IN HEALTH, 2019, 22 : S466 - S467
  • [47] Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
    Moy, Beverly
    Neven, Patrick
    Lebrun, Fabienne
    Bellet, Meritxell
    Xu, Binghe
    Sarosiek, Tomasz
    Chow, Louis
    Goss, Paul
    Zacharchuk, Charles
    Leip, Eric
    Turnbull, Kathleen
    Bardy-Bouxin, Nathalie
    Duvillie, Ladan
    Lang, Istvan
    ONCOLOGIST, 2014, 19 (04): : 348 - 349
  • [48] An evidence-based review of the outcome of fulvestrant plus a targeted agent versus fulvestrant alone in treating hormone receptor-positive endocrine therapy-resistant metastatic breast cancer
    Hua, Yu-Ming
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2019, 300 (05) : 1377 - 1382
  • [49] An evidence-based review of the outcome of fulvestrant plus a targeted agent versus fulvestrant alone in treating hormone receptor-positive endocrine therapy-resistant metastatic breast cancer
    Yu-Ming Hua
    Archives of Gynecology and Obstetrics, 2019, 300 : 1377 - 1382
  • [50] Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib plus letrozole: results from MONALEESA-2
    Verma, Sunil
    O'Shaughnessy, Joyce
    Burris, Howard A.
    Campone, Mario
    Alba, Emilio
    Chandiwana, David
    Dalal, Anand A.
    Sutradhar, Santosh
    Monaco, Mauricio
    Janni, Wolfgang
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (03) : 535 - 545
12345